Antiarrhythmic effects of ORG 6001 in rats: Correlation with plasma and tissue drug concentrations

British Journal of Pharmacology (Impact Factor: 4.84). 03/1982; 75(2):319-23. DOI: 10.1111/j.1476-5381.1982.tb08789.x
Source: PubMed


The antiarrhythmic effects of Org 6001 following oral administration in the rat have been assessed and correlated with plasma, myocardial and skeletal muscle drug concentrations. Arrythmias were induced by coronary artery ligation in anaesthetized rats. Org 6001 (10, 20, 50 and 100 mg/kg given 1 h before ligation) significantly reduced mortality and the incidence of ventricular fibrillation in the 0-30 min post ligation period. Only the highest dose of drug also significantly reduced the number of ventricular ectopic beats following ligation. A linear relationship was observed between the oral dose and the Org 6001 concentrations in plasma and skeletal muscle determined 90 min after drug administration. The Org 6001 concentration in the myocardium was not linearly related to the administered dose and Org 6001 appeared to be concentrated to a higher extent in cardiac than in skeletal muscle at that time. No statistically significant difference in drug levels in the ischaemic left ventricle and normal right ventricle plus septum was observed. The antiarrythmic effect of Org 6001, as measured by changes in the incidence of ventricular fibrillation, correlated with myocardial concentrations of the drug.

Download full-text


Available from: Fiona M Mcdonald, Sep 30, 2015
  • [Show abstract] [Hide abstract]
    ABSTRACT: The initial discovery that a compound possesses antiarrhythmic activity is usually made in simple screening models involving the use of arrhythmogenic chemicals like aconitine, chloroform or ouabain. If promising results are obtained in these tests then the potential antiarrhythmic drug may be tested (usually in conscious dogs) for its ability to suppress ventricular ectopic activity ensuing 1–2 days after the production of myocardial ischaemia. Historically this sequence of events holds especially for the group of drugs variously described as ‘membrane stabilisers’, ‘sodium channel blockers’ or ‘class 1 agents’ (Vaughan Williams, 1970). Consequently, there is comparatively little literature describing the effects of sodium channel blocking agents on the early experimental ventricular arrhythmias and fibrillation which occur within minutes of the onset of myocardial ischaemia. The reasons for this are many but surely include the difficulties involved in producing a consistent quantitative model in which to assess the protective actions of putative antiarrhythmic drugs. For instance, our own experiences have shown that one-stage coronary artery ligation does not produce ventricular ectopic activity in every species — rabbits and guineapigs being particularly resistant. In addition even in those species which demonstrate early ventricular arrhythmias (for example, the dog), ligation of the same coronary artery can be associated with a range of incidence of ventricular fibrillation (VF) of between zero and 100 per cent depending on the laboratory (see Stephenson et al., 1960, for review of early literature, and chapter 6 of this book).
    No preview · Article · Jan 1982
  • [Show abstract] [Hide abstract]
    ABSTRACT: The effects of lidocaine (5 or 10 mg/kg bolus + 2.5 mg/kg/h) on arrhythmias and changes in myocardial and plasma catecholamines (CAs) after left coronary artery occlusion were investigated in anesthetized rats. Myocardial intraneuronal CAs were assessed histofluorimetrically and CA concentrations were measured using high-pressure liquid chromatography (HPLC). Both doses of lidocaine caused reductions in heart rate and blood pressure. The higher dose significantly reduced the number of ischemia-induced ventricular extrasystoles from 425 +/- 123 to 25 +/- 12 in the first 60 min of ischemia and abolished ventricular tachycardia and fibrillation. In the myocardium of untreated animals, the area of fluorescing adrenergic neurons (as percentage of total field area) was 0.42 +/- 0.02% after 60 min of ischemia as compared with 1.38 +/- 0.17% in sham-operated animals. Lidocaine pretreatment resulted in a dose-dependent inhibition of this ischemia-induced CA release from adrenergic neurons (0.96 +/- 0.06 and 1.30 +/- 0.05% for the lower and higher dose, respectively). Tissue and plasma CA concentrations were not significantly affected by lidocaine pretreatment and by coronary occlusion. It is concluded that lidocaine inhibits CA release from sympathetic nerve endings in the ischemic myocardium by its endoanesthetic and membrane-stabilizing properties. The reduction in CA release may also contribute to its antiarrhythmic effects.
    No preview · Article · Feb 1987 · Journal of Cardiovascular Pharmacology

  • No preview · Article · May 1987 · Journal of Molecular and Cellular Cardiology
Show more